Deal sells units of series A convertible preferreds with common shares
By Devika Patel
Knoxville, Tenn., March 24 – Regen BioPharma, Inc. completed a $265,000 private placement of units between Jan. 28 and March 22, according to an 8-K filed Thursday with the Securities and Exchange Commission.
On Jan. 28, the company sold 1 million units of two common shares and one series A convertible preferred for $150,000.
Between Jan. 28 and Feb. 2, the company sold 300,000 units of one common share and one series A convertible preferred for $15,000.
On Feb. 22, the company sold 333,333 units of two common shares and one series A convertible preferred for $50,000.
On March 22, the company sold 1 million units of one common share and three series A convertible preferreds for $50,000.
Proceeds will be used for general corporate purposes.
Based in La Mesa, Calif., Regen BioPharma focuses on the development of translational medicine platforms for the commercialization of stem cell therapies.
| Issuer: | Regen BioPharma, Inc.
|
| Issue: | Units of two common shares and one series A convertible preferred; units of one common share and one series A convertible preferred; units of one common share and three series A convertible preferreds
|
| Amount: | $265,000
|
| Units: | 2,633,333
|
| Warrants: | No
|
| Settlement dates: | Jan. 28 (for $150,000), between Jan. 28 and Feb. 2 (for $15,000), Feb. 22 (for $50,000), March 22 (for $50,000)
|
| Stock symbol: | OTCBB: XPWR
|
| Stock price: | $0.12 at close Jan. 27
|
| Market capitalization: | $17.4 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
